08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Biolife Science, Imugene deal

Imugene completed its acquisition of Biolife for 300 million shares of Imugene stock, or about A$4.5 million ($4 million) based on Imugene's close of A$0.015 on Dec. 18, before the deal closed (see BioCentury, Oct....
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Biolife Science, Imugene deal

Drug delivery company Imugene will acquire Biolife for 300 million shares of Imugene stock, or about A$3.6 million ($3.5 million) based on Imugene's close of A$0.012 on Oct. 18, before the deal was announced. Imugene...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Acuvax, Biolife Science Ltd. deal

Biolife will reverse-merge with Acuvax in a stock deal. Acuvax will issue 20 million of its shares to Biolife up front. Acuvax will own 100% of Biolife and Acuvax will be renamed Biolife Science Ltd....